These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 9083157

  • 1. Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen.
    Beguin Y, Sautois B, Forget P, Bury J, Fillet G.
    Cancer; 1997 Apr 01; 79(7):1351-4. PubMed ID: 9083157
    [Abstract] [Full Text] [Related]

  • 2. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 3. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
    Jehn U, Zittoun R, Suciu S, Fiere D, Haanen C, Peetermans M, Löwenberg B, Willemze R, Solbu G, Stryckmans P.
    Haematol Blood Transfus; 1990 Dec 15; 33():277-84. PubMed ID: 1691132
    [Abstract] [Full Text] [Related]

  • 4. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.
    Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, Tomonaga M, Tsubaki K, Takahashi I, Kodera Y.
    Cancer; 1993 Jun 15; 71(12):3888-95. PubMed ID: 8508355
    [Abstract] [Full Text] [Related]

  • 5. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
    Latagliata R, Breccia M, Fazi P, Iacobelli S, Martinelli G, Di Raimondo F, Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A, Amadori S, Caramatti C, Falzetti F, Candoni A, Mattei D, Morselli M, Alimena G, Vignetti M, Baccarani M, Mandelli F.
    Br J Haematol; 2008 Dec 15; 143(5):681-9. PubMed ID: 18950458
    [Abstract] [Full Text] [Related]

  • 6. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K.
    Leukemia; 1990 Mar 15; 4(3):177-83. PubMed ID: 2179638
    [Abstract] [Full Text] [Related]

  • 7. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB.
    Leukemia; 1991 Jun 15; 5(6):510-6. PubMed ID: 2056774
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR, Weiner RS, Moore JO, Omura GA, Bartolucci AA, Stagg M.
    Leukemia; 1995 Sep 15; 9(9):1456-60. PubMed ID: 7544851
    [Abstract] [Full Text] [Related]

  • 9. [Induction and intensive combined therapy of acute myeloid leukemia in adults].
    Kurrle E, Ehninger G, Freund M, Heil G, Hoelzer D, Link H, Mitrou PS, Ohl S, Queisser W, Schlimok G.
    Onkologie; 1988 Feb 15; 11(1):5-9. PubMed ID: 3283626
    [Abstract] [Full Text] [Related]

  • 10. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
    Phillips GL, Reece DE, Shepherd JD, Barnett MJ, Brown RA, Frei-Lahr DA, Klingemann HG, Bolwell BJ, Spinelli JJ, Herzig RH.
    Blood; 1991 Apr 01; 77(7):1429-35. PubMed ID: 2009367
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy.
    Oberg G, Killander A, Björeman M, Gahrton G, Grimfors G, Gruber A, Hast R, Lerner R, Liliemark J, Mattson S, Paul C, Simonsson B, Stalfelt AM, Stenke L, Tidefelt U, Udén AM, Björkholm M, LGMS.
    Eur J Haematol; 2002 Jun 01; 68(6):376-81. PubMed ID: 12225396
    [Abstract] [Full Text] [Related]

  • 12. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.
    Ann Hematol; 2014 Dec 01; 93(12):2011-8. PubMed ID: 24989345
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City].
    Zhonghua Nei Ke Za Zhi; 1992 Mar 01; 31(3):139-42, 187. PubMed ID: 1395923
    [Abstract] [Full Text] [Related]

  • 14. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Fabères C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P.
    Leukemia; 1996 Mar 01; 10(3):389-95. PubMed ID: 8642852
    [Abstract] [Full Text] [Related]

  • 15. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
    Meloni G, Vignetti M, Avvisati G, Capria S, Micozzi A, Giona F, Mandelli F.
    Bone Marrow Transplant; 1996 Oct 01; 18(4):693-8. PubMed ID: 8899182
    [Abstract] [Full Text] [Related]

  • 16. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
    Taguchi H, Kubonishi I, Takehara N, Uemura Y, Iwahara Y, Eguchi T, Miyagi T, Sugito S, Muneishi H, Tanaka Y.
    Gan To Kagaku Ryoho; 1992 Aug 01; 19(9):1309-14. PubMed ID: 1503485
    [Abstract] [Full Text] [Related]

  • 17. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K, Ritter J, Schellong G, Beck JD, Kabisch H, Lampert F, Creutzig U.
    Klin Padiatr; 1992 Dec 15; 204(4):253-7. PubMed ID: 1518261
    [Abstract] [Full Text] [Related]

  • 19. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
    Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G.
    J Clin Oncol; 1985 Dec 15; 3(12):1583-9. PubMed ID: 3906048
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
    Jehn U.
    Leuk Lymphoma; 1994 Sep 15; 15(1-2):99-112. PubMed ID: 7532060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.